A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs HMPL-306 (Primary)
- Indications Cholangiocarcinoma; Chondrosarcoma; Glioma; Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma; HUTCHMED
- 23 Oct 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
- 23 Oct 2024 Planned primary completion date changed from 30 Mar 2024 to 30 Mar 2025.
- 02 Feb 2024 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.